Immunocore Holdings stock
IMCRNASDAQImmunocore Holdings plc, HealthcareISIN US45258D1054
45Score 45 out of 100, Weak
Price and trend
51 / 100
Price history
−14% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.5% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 24% below its 52-week high. Largest decline in 6 years: 67% (February 2024 to April 2025).
Chart figures for advanced users
- SMA 50$31.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.60
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$27.79
- The lowest closing price of the last twelve months.
- Resistance$40.22
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Immunocore Holdings plc belongs to the Biotechnology industry (United Kingdom) and, with a market value of $1.57B, is number 149 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $400.02M (up 28.8% year on year) and a loss of $35.51M.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 455 of 702 in Healthcare, median 53.
- Our model puts fair value at $58.74, with the price 48% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 198.3% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $864.15M, financial debt $436.69M (fiscal 2025).Stability 50
Weaknesses
- DilutionShare count up 58% since 2020.Capital allocation 18
- Loss-makingLoss of $32.12M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$18.21M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 45.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $45.18 and expensive above $83.91 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 11.2%. At 12.2% the fair value would be $49.89, at 10.2% it would be $70.49.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.1% on the twelve months before. Up to 2023 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 198.3% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating −11%, net −9%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 6 Nov 2026below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 31.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −0.07−31.9%
- Revenue
- $452.62M+0.1%
- Earnings per share
- −0.77−30.1%
- Revenue
- $482.05M−1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Jallal BahijaSale
18 Feb 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 11,474
- Price
- $32.35
- Value
- $371,184
- Goll JohnSale
18 Feb 2026, SVP, FINANCE & CAO
- Shares
- 698
- Price
- $32.35
- Value
- $22,580
- St Leger Tina AmberSale
18 Feb 2026, CHIEF HR OFFICER
- Shares
- 1,000
- Price
- $32.35
- Value
- $32,350
Show 5 more
- Berman David MSale
18 Feb 2026, HEAD OF R&D
- Shares
- 5,965
- Price
- $32.35
- Value
- $192,968
- Berman David MSale
5 Dec 2025, HEAD OF R&D
- Shares
- 572
- Price
- $40.14
- Value
- $22,960
- Berman David MSale
4 Dec 2025, HEAD OF R&D
- Shares
- 31,341
- Price
- $40.26
- Value
- $1.26M
- Berman David MSale
28 Nov 2025, HEAD OF R&D
- Shares
- 5,521
- Price
- $40.09
- Value
- $221,337
- Berman David MSale
26 Nov 2025, HEAD OF R&D
- Shares
- 69,404
- Price
- $40.12
- Value
- $2.78M
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Immunocore Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Ultragenyx PharmaceuticalRARE $1.66B38
- NanobiotixNANO.PA $1.64B38
- SELLAS Life Sciences GroupSLS $1.62B35
- Generate BiomedicinesGENB $1.61B36
- AbsciABSI $1.57B38
- Intellia TherapeuticsNTLA $1.48B33
- NovavaxNVAX $1.45B42
- Nuvation BioNUVB $1.43B29
ETFs that hold Immunocore Holdings
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.25B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.